Sophia Delicou, MD, Hippokration General Hospital, Athens, Greece, comments on the impact of luspatercept and mitapivat on transfusion dependence in thalassemia. Both agents have shown promising results in reducing transfusion needs, with luspatercept helping some patients become entirely transfusion-independent. In the ENERGIZE-T trial (NCT04770779), mitapivat showed a significant reduction in transfusion needs of patients with alpha- and beta-thalassemia, with up to 10% of participants not requiring transfusions for at least eight weeks. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
